Abbott, Rubicon in MethylPlex pact:
This article was originally published in Clinica
Executive Summary
Rubicon Genomics is to team up with Abbott Molecular to develop cancer tests using Rubicon's MethylPlex methylation detection technology. Under the multi-year research and option agreement, the two companies will focus primarily on noninvasive detection of prostate and bladder cancer. According to Ann Arbor, Michigan-based Rubicon, its MethylPlex technology offers a highly sensitive method for detecting the patterns of abnormal DNA methylation arising in serum and urine during tumour formation and progression.